Literature DB >> 9774554

Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use.

J Ter Meulen1, K Koulemou, T Wittekindt, K Windisch, S Strigl, S Conde, H Schmitz.   

Abstract

The nucleoprotein of Lassa virus, strain Josiah, was expressed in Escherichia coli as an N-terminally truncated, histidine-tagged recombinant protein. Following affinity purification the protein was completely denatured and spotted onto nitrocellulose membrane. A total of 1 microgram of protein was applied for detection of Lassa virus antibodies (LVA) in a simple immunoblot assay. Specific anti-Lassa immunoglobulin M (IgM) antibodies could be detected by increasing the amount of protein to 5 microgram. A panel of 913 serum specimens from regions in which Lassa virus was endemic and from regions in which Lassa virus was not endemic was used for evaluating the sensitivity and specificity of the LVA immunoblot in comparison to those of an indirect immunofluorescence (IIF) assay. The sera originated from field studies conducted in the Republic of Guinea (570 serum samples) and Liberia (99 serum samples), from inpatients of the clinical department of the Bernhard-Nocht-Institute, Hamburg, Germany (94 serum samples), and from healthy German blood donors (150 serum samples). In comparison to the IIF assay the LVA immunoblot assay had a specificity of 90.0 to 99.3%, depending on the origin of the specimens. The sensitivity was found to be highest for the Guinean samples (90.7%) and was lower for the Liberian samples (75%). Acute Lassa fever was diagnosed by PCR in 12 of 59 (20.3%) patients with fever of unknown origin (FUO) from the Republic of Guinea. On admission to the hospital, nine Lassa fever patients (75%) were reactive by the IgM immunoblot assay. One of the patients was infected with a new Lassa variant, which showed 10.4% variation on the amino acid level in comparison to the prototype strain of Lassa virus, Josiah. Seven PCR-negative patients were reactive by immunoblotting. The positive and negative predictive values of a single IgM immunoblot result for acute, PCR-confirmed Lassa fever were therefore 53.6 and 93.0%, respectively. Because of its high negative predictive value, a single IgM immunoblot result will be valuable for excluding acute Lassa fever for cases of FUO in areas where Lassa fever is endemic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774554      PMCID: PMC105290     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections.

Authors:  H Wulff; K M Johnson
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

2.  Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis.

Authors:  B Hjelle; S Jenison; N Torrez-Martinez; B Herring; S Quan; A Polito; S Pichuantes; T Yamada; C Morris; F Elgh; H W Lee; H Artsob; R Dinello
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea.

Authors:  J Ter Meulen; I Lukashevich; K Sidibe; A Inapogui; M Marx; A Dorlemann; M L Yansane; K Koulemou; J Chang-Claude; H Schmitz
Journal:  Am J Trop Med Hyg       Date:  1996-12       Impact factor: 2.345

4.  A case-control study of the clinical diagnosis and course of Lassa fever.

Authors:  J B McCormick; I J King; P A Webb; K M Johnson; R O'Sullivan; E S Smith; S Trippel; T C Tong
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

5.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci.

Authors:  P C Sham; D Curtis
Journal:  Ann Hum Genet       Date:  1995-01       Impact factor: 1.670

6.  Detection of human antibodies to Crimean-Congo haemorrhagic fever virus using expressed viral nucleocapsid protein.

Authors:  A C Marriott; T Polyzoni; A Antoniadis; P A Nuttall
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

7.  Expression of Lassa virus nucleocapsid protein segments in bacteria: purification of high-level expression products and their application in antibody detection.

Authors:  G N Barber; J C Clegg; J Chamberlain
Journal:  Gene       Date:  1987       Impact factor: 3.688

8.  Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay.

Authors:  B S Niklasson; P B Jahrling; C J Peters
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

9.  A prospective study of the epidemiology and ecology of Lassa fever.

Authors:  J B McCormick; P A Webb; J W Krebs; K M Johnson; E S Smith
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

10.  Structural and cell-associated proteins of Lassa virus.

Authors:  J C Clegg; G Lloyd
Journal:  J Gen Virol       Date:  1983-05       Impact factor: 3.891

View more
  19 in total

1.  Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.

Authors:  D G Bausch; P E Rollin; A H Demby; M Coulibaly; J Kanu; A S Conteh; K D Wagoner; L K McMullan; M D Bowen; C J Peters; T G Ksiazek
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA.

Authors:  Stephan Olschläger; Michaela Lelke; Petra Emmerich; Marcus Panning; Christian Drosten; Meike Hass; Danny Asogun; Deborah Ehichioya; Sunday Omilabu; Stephan Günther
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Rapid detection of Lassa virus by reverse transcription-loop-mediated isothermal amplification.

Authors:  Aiko Fukuma; Yohei Kurosaki; Yuko Morikawa; Allen Grolla; Heinz Feldmann; Jiro Yasuda
Journal:  Microbiol Immunol       Date:  2011-01       Impact factor: 1.955

Review 4.  Laboratory Diagnosis of Lassa Fever.

Authors:  Vanessa Raabe; Jeffrey Koehler
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

5.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

6.  Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Authors:  J ter Meulen; M Badusche; K Kuhnt; A Doetze; J Satoguina; T Marti; C Loeliger; K Koulemou; L Koivogui; H Schmitz; B Fleischer; A Hoerauf
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Genetic diversity among Lassa virus strains.

Authors:  M D Bowen; P E Rollin; T G Ksiazek; H L Hustad; D G Bausch; A H Demby; M D Bajani; C J Peters; S T Nichol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.

Authors:  S Günther; P Emmerich; T Laue; O Kühle; M Asper; A Jung; T Grewing; J ter Meulen; H Schmitz
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

10.  Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever.

Authors:  Masayuki Saijo; Marie-Claude Georges-Courbot; Philippe Marianneau; Victor Romanowski; Shuetsu Fukushi; Tetsuya Mizutani; Alain-Jean Georges; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2007-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.